Icro Meattini, MD, University of Florence, Florence, Italy, shares the results of the Phase II ROCK (NCT03520894) trial exploring preoperative robotic radiosurgery for early breast cancer. The study aimed to prospectively assess the safety and feasibility of a single Cyberknife 21Gy-fraction preoperative robotic radiosurgery in preoperative setting, and to identify predictive factors for outcomes based on biologic and clinical features. The primary endpoint was the acute skin toxicity. Secondary endpoints included the rate of early late skin and non-skin toxicity as measured 90 days from the end of preoperative robotic radiosurgery. The trial showed that a single 21 Gy dose exploring preoperative robotic radiosurgery represents a feasible technique for patient with early breast cancer, demonstrating a good safety profile and a promising effectiveness. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.